Frequently Asked Questions about Bicara Therapeutics Inc. Common Stock (BCAX)

Name: Bicara Therapeutics Inc. Common Stock (BCAX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Bicara Therapeutics Inc. Common Stock (BCAX) do?

Accepted Answer

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human...

Question 2

Is Bicara Therapeutics Inc. Common Stock (BCAX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of BCAX reveals an Altman Z-Score of 23.13 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if BCAX fits their risk profile.

Question 3

What is the current P/E ratio for BCAX?

Accepted Answer

As of the latest trading session, Bicara Therapeutics Inc. Common Stock (BCAX) has a trailing P/E ratio of -8.33.

Question 4

Who is the CEO of Bicara Therapeutics Inc. Common Stock?

Accepted Answer

The current Chief Executive Officer of Bicara Therapeutics Inc. Common Stock is Claire Mazumdar Clemon.

Question 5

What was BCAX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Bicara Therapeutics Inc. Common Stock reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022) respectively.

Question 6

Does BCAX pay a dividend?

Accepted Answer

Bicara Therapeutics Inc. Common Stock does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does BCAX have?

Accepted Answer

In its latest reporting period, Bicara Therapeutics Inc. Common Stock generated $-0.11B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Bicara Therapeutics Inc. Common Stock?

Accepted Answer

The Price-to-Book (P/B) ratio for Bicara Therapeutics Inc. Common Stock (BCAX) is currently 2.86.

Question 9

What is the Price-to-Sales (P/S) ratio of BCAX?

Accepted Answer

Based on trailing twelve-month data, Bicara Therapeutics Inc. Common Stock (BCAX) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Bicara Therapeutics Inc. Common Stock's Return on Equity (ROE)?

Accepted Answer

Bicara Therapeutics Inc. Common Stock (BCAX) has a Return on Equity (ROE) of -32.49%, representing its profitability relative to shareholder equity.

BCAX

Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High – Here’s Why

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High on Analyst Upgrade

Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade

Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement

Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript